July 28, 2016 2:24 PM ET

Pharmaceuticals

Company Overview of Sound Pharmaceuticals, Inc.

Company Overview

Sound Pharmaceuticals, Inc., a biopharmaceutical company, develops prescription drugs that enable doctors and patients to prevent and treat hearing loss. It develops therapies for acquired forms of sensorineural hearing loss. The company was incorporated in 2001 and is based in Seattle, Washington.

4010 Stone Way North

Suite 120

Seattle, WA 98103

United States

Founded in 2001

Phone:

206-634-2559

Fax:

206-634-2342

Key Executives for Sound Pharmaceuticals, Inc.

Chief Executive Officer
President and Director
Chief Financial Officer
Compensation as of Fiscal Year 2016.

Sound Pharmaceuticals, Inc. Key Developments

Sound Pharmaceuticals, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-13-2016 11:20 AM

Sound Pharmaceuticals, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-13-2016 11:20 AM. Venue: The Westin NY Grand Central Hotel, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Jonathan Kil, Chief Executive Officer.

Sound Pharmaceuticals Appoints Paul Rickey as Chief Financial Officer

Sound Pharmaceuticals announced the appointment of Paul Rickey as Chief Financial Officer (CFO). Paul Rickey joined the company effective March 1, 2016. Paul will lead the company's financial and administrative operations. Prior to his appointment at Sound Pharmaceuticals, Paul served as Vice President of Finance and Administration of Immune Design Corp., where he helped complete the company's private offerings, initial public offering, and follow-on financing. In addition, he oversaw the finance, accounting and human resource functions through July of 2015.

Sound Pharmaceuticals and University of Oxford Collaborate on New Treatment for Bipolar Disorder

Sound Pharmaceuticals (SPI) will collaborate with the University of Oxford on a Phase 2 clinical trial to test SPI-1005 for the treatment of bipolar disorder. Bipolar disorder is a psychiatric illness that involves both periods of mania and depression, and affects approximately 1% of adults worldwide. Unfortunately, patients have relatively few treatment options, often involving drugs such as lithium, which have significant side effects. SPI-1005 is an oral drug that contains ebselen, which mimics and induces the activity of Glutathione Peroxidase (GPx) in the brain and inner ear. SPI-1005 is under clinical investigation in several otologic diseases where GPx activity is reduced, including noise-induced hearing loss, chemotherapy-induced ototoxicity and Meniere's disease. GPx activity is thought to be diminished in several psychiatric disorders including bipolar, schizophrenia and autism, and neurologic diseases including traumatic brain injury, stroke, dementia, and Parkinson's.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 7, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sound Pharmaceuticals, Inc., please visit www.soundpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.